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Downstaging can facilitate liver transplantation (LT) for patients outside of Milan criteria with hepatocellular carcinoma
(HCC); however, the optimal protocol and downstaging outcomes are poorly defined. We aimed to characterize rates of suc-
cessful downstaging to within Milan criteria and post-LT recurrence and survival among patients who underwent
downstaging. We performed a systematic literature review using the MEDLINE and Embase databases from January 1996
through March 2015 and a search of national meeting abstracts from 2010 to 2014. Rates of downstaging success (defined
as a decrease of tumor burden to within Milan) and post-LT recurrence with 95% confidence intervals (CIs) were calculated.
Prespecified subgroup analyses were conducted by treatment modality, study design, and patient characteristics. Thirteen
studies (n 5 950 patients) evaluating downstaging success had a pooled success rate of 0.48 (95% CI, 0.39-0.58%). In
subgroup analyses, there was no significant difference comparing transarterial chemoembolization (TACE) versus transarte-
rial radioembolization (TARE; P 5 0.51), but there were higher success rates in prospective versus retrospective studies
(0.68 versus 0.44; P < 0.001). The 12 studies (n 5 320 patients) evaluating post-LT HCC recurrence had a pooled recur-
rence rate of 0.16 (95% CI, 0.11-0.23). There was no significant difference in recurrence rates between TACE and TARE (P
5 0.33). Post-LT survival could not be aggregated because of heterogeneity in survival data reporting. Current data have
heterogeneity in baseline tumor burden, waiting time, downstaging protocols, and treatment response assessments. There
are also notable limitations including inconsistent reporting of inclusion criteria, downstaging protocols, and outcome
assessment criteria. In conclusion, the success rate of downstaging HCC to within Milan criteria exceeds 40%; however,
posttransplant HCC recurrence rates are high at 16%. Downstaging protocols for HCC should be systematically studied and
optimized to minimize the risk of post-LT HCC recurrence. Liver Transpl 21:1142-1152, 2015. VC 2015 AASLD.
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Liver transplantation (LT) is a lifesaving and curative
treatment for patients with hepatocellular carcinoma
(HCC). LT has been shown to provide the best long-
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term survival for these patients, as it both cures the
HCC and underlying liver disease.1 The number and
proportion of LTs for HCC has increased in recent
years, making it a leading indication for transplanta-
tion.2 The Milan criteria for LT (1 tumor less than 5
cm, up to 3 tumors less than 3 cm in size) has been
proposed, validated, and widely used as the eligibility
criteria for consideration of LT in the treatment of
HCC.3 Data from numerous cohorts of patients have
shown that outcomes for LT in patients within Milan
criteria are excellent with high survival rates and low
recurrence rates. Overall, post-LT survival rates are
comparable to patients transplanted without HCC.4,5
Unfortunately, only a minority of HCC patients pres-
ent within Milan criteria.6 If patients present outside
Milan criteria, LT is often not an option at many
transplant centers and patients are left with no other
curative options for their HCC. For selected patients,
downstaging is attempted to bring tumors within
Milan criteria by using liver-directed therapy. Options
for conducting downstaging include radiofrequency
ablation (RFA), transarterial chemoembolization
(TACE), transarterial radioembolization (TARE), ste-
reotactic body radiation (SBRT), or a combination of
therapies. The benefits of downstaging include
decreasing tumor burden and allowing time to identify
those with less aggressive tumor biology.
There have been numerous reports of using
downstaging to bring patients within transplant crite-
ria; however, these data are largely restricted to small
cohorts of patients and include disparate downstaging
protocols. Therefore, the success rates and posttrans-
plant outcomes after downstaging are largely unknown
outside of single-center reports. We hypothesize that
downstaging yields high success rates but is associ-
ated with high post-LT recurrence rates. To better
characterize the efficacy of downstaging, we performed
a meta-analysis of observational studies with indi-
viduals beyond Milan criteria who underwent
downstaging with locoregional therapies. The aims of
this meta-analysis were (1) to determine the success of
downstaging HCC to bring patients within Milan crite-
ria and (2) to characterize post-LT recurrence rates
and survival of patients who were downstaged.
PATIENTS AND METHODS
Literature Search
Two study investigators (N.D.P. and A.G.S.) independ-
ently conducted a computer-assisted search of the
MEDLINE and Embase databases to identify relevant
published articles. We searched the databases from
January 1, 1996 through March 1, 2015 with the fol-
lowing keyword combinations: (downstaging OR down
staging OR downstage OR down stage) AND (hepato-
cellular carcinoma OR HCC OR liver cancer). Our
search was limited to human studies published in
English. Manual searches of references from relevant
articles were performed to identify studies that were
missed by our computer-assisted search. Additional
manual searches of Digestive Diseases Week, Ameri-
can Association for the Study of Liver Diseases, Euro-
pean Association for the Study of the Liver (EASL),
American College of Gastroenterology, and the Inter-
national Liver Cancer Association from 2010 to 2014
were performed.
Study Selection
The search for studies and study selection was con-
ducted with meta-analysis of observational studies in
epidemiology (MOOSE) and Preferred Reporting Items
for Systematic Reviews and Meta-analysis (PRISMA)
guidance.7,8 Two investigators (N.D.P. and A.G.S.)
reviewed all publication titles of citations identified by
the search strategy. Potentially relevant studies were
retrieved, and selection criteria were applied. The
articles were independently checked for inclusion by 2
investigators (N.D.P. and A.G.S.), disagreements were
resolved through discussion, and consensus was
reached on all articles. Our inclusion criteria were (1)
cohort studies (retrospective or prospective); (2) stud-
ies evaluating downstaging in patients with cirrhosis
and HCC; (3) studies in which downstaging was per-
formed using surgical resection, RFA, TACE, TARE,
SBRT, or a combination of therapies; and (4) studies
that reported rates of success for downstaging
patients to within Milan criteria using imaging criteria
and/or posttransplant outcomes (including recur-
rence rates and/or survival) among those who were
downstaged to within Milan criteria. We excluded
articles that (1) evaluated investigational procedures;
(2) evaluated systemic chemotherapeutic agents; (3)
used explant data for evaluation of downstaging suc-
cess; (4) had incomplete data for primary outcomes of
interest; (5) included less than 5 patients; and/or (6)
used surgical resection as the only method for
downstaging patients. Studies in which a minority of
patients had surgical resection as a downstaging
modality were included. For studies that reported on
duplicate cohorts of patients, we used the most
updated cohort or the publication that provided the
most complete baseline and follow-up data. Additional
exclusion criteria included non-English language and
nonhuman data.
Data Extraction
Two investigators (N.D.P. and A.G.S.) independently
extracted required information from eligible studies
using standardized forms developed by the investiga-
tors. We collected data on study design (retrospective
versus prospective), inclusion/exclusion criteria,
modality of downstaging treatment, baseline liver
function, pretreatment tumor burden, waiting time to
LT, requirement for mandatory wait time before LT,
posttreatment tumor burden, time to recurrence after
LT, post-LT survival, and overall length of follow-up.
Authors were contacted via e-mail for any missing infor-
mation. Study quality was rated by 1 investigator
(N.D.P.) using the modified Newcastle-Ottawa scale
(NOS).9 This instrument rates observational studies on a
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9-point scale on the basis of appropriateness of study
sample, comparability of study groups, and adequacy of
assessing exposure and outcomes. Studies with a score
greater than7were considered high quality.
Clinical Endpoints and Statistical Analysis
The primary outcomes of interest were (1) success
rate of downstaging to within Milan criteria and (2)
HCC recurrence rates after LT. We also characterized
post-LT survival but did not perform a pooled analysis
given heterogeneity in the reporting of survival
data. For both primary meta-analysis outcomes, we
transformed proportions into a quantity using the
Freeman-Tukey variant of the arcsine square root–
transformed proportion.10 Pooled proportions for each
outcome were calculated as a back-transform of the
weighted mean of the transformed proportions using
a random effects model. Heterogeneity was assessed
using the I2 test and subset analyses.11 Subset analy-
ses were planned for the following predefined subsets
of studies: (1) TACE versus TARE; (2) prospective ver-
sus retrospective study design; (3) proportion of
Child-Pugh class A patients; and (4) study quality. We
included liver function as an a priori subset analysis
given patients with preserved liver function may toler-
ate more aggressive and/or more cycles of
downstaging treatment than patients with marginal
liver function. We initially planned to do subset analy-
ses based on baseline tumor burden, but this was not
deemed possible given insufficient patient-level data.
Publication bias was assessed by visual inspection of
a funnel plot.12 All analyses were conducted in Stata
13.1 (StataCorp, College Station, TX).
RESULTS
Literature Search
The computer-aided search yielded 139 original
articles, and the abstract of each article was reviewed.
After reviewing the abstracts, 47 studies were inde-
pendently reviewed by both investigators. After exclu-
sions were applied, a total of 15 published studies
were included in the final analysis. A review of the
meeting abstract proceedings revealed 2 additional
relevant studies for inclusion (Fig. 1). There were 13
studies with 950 unique patients which described the
success of downstaging patients to within Milan
criteria13-25 (Table 1) and 15 studies with 320 unique
patients which described posttransplant recurrence
rates among patients who were downstaged (Table
2).13-16,19-30 Funnel-plot analysis showed similar
effects among small and large studies for both out-
comes with no evidence of publication bias (Support-
ing Figs. 1 and 2).
Study Characteristics
The majority of patients in the included trials had
Child-Pugh class A disease (54%), whereas patients
with Child-Pugh class B (36%) and Child-Pugh class
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C (8%) cirrhosis were less common. Initial tumor bur-
den varied among studies (Table 1); however, only 2
studies included patients with tumor thrombus.13,18
Five studies (n 5 230 patients) used TACE as the pri-
mary downstaging modality, and 4 studies (n 5 88
patients) used TARE. Three studies (n 5 198 patients)
described downstaging success in patients undergoing
multimodal therapy. A minority of patients in multimo-
dal studies (n 5 15, 8%) underwent surgical resection
as a downstaging modality. The number of treatment
sessions and interval between treatment were not well
described in the included studies. The imaging criteria
used to define downstaging success also varied sub-
stantially, with EASL criteria being used in 4 studies,
modified Response Evaluation Criteria in Solid Tumors
(mRECIST) in 3 studies, RECIST in 3 studies, both
EASL and World Health Organization (WHO) criteria in
1 study, and unspecified criteria in 2 studies.
After downstaging, 87 patients who underwent TACE
and 15 patients who underwent TARE underwent LT.
A total of 118 patients underwent LT after a multimo-
dal downstaging approach. The waiting time between
initiation of downstaging and LT as well as follow-up
time after LT were inconsistently reported (Table 2).
Figure 2. Pooled downstaging success stratified by prospective versus retrospective study design.
Figure 1. Search strategy.
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The quality of the included studies was primarily
limited by small sample sizes, lack of comparator
groups, poorly defined inclusion criteria, and/or
inconsistent outcome assessment. The NOS quality
scores are included in Table 2.
Downstaging Success
There was heterogeneity in downstaging success rate
among included studies (I2 5 84.8%), with an aggre-
gate success rate of 0.48% (95% confidence interval
Figure 4. Pooled post-LT HCC recurrence stratified by prospective versus retrospective study design.
Figure 3. Pooled downstaging success stratified by treatment modality (TACE versus TARE).
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[CI], 0.39%-0.58%). Studies that included patients
with tumor thrombus had the lowest success rates;
when these studies were excluded, the pooled success
rate was 0.54% (95% CI, 0.45%-0.63%). Studies with
prospectively designed protocols for downstaging also
yielded a significantly higher success rate compared
to retrospective studies (0.68% versus 0.44% P <
0.001; Fig. 2). There was no significant difference in
the success rate of TACE and TARE for downstaging
(0.48% versus 0.37%; P 5 0.51; Fig. 3); however, the
highest downstaging success rates were reported in
cohorts undergoing multimodal therapy for
downstaging. The 3 studies using multimodal locore-
gional therapy (n 5 198 patients) had a significantly
higher pooled downstaging success rate when com-
pared to the success with TACE/TARE (0.66; 95% CI,
0.58-0.73; P < 0.001).20,21,25 Contrary to our original
hypothesis, studies including higher proportions of
Child-Pugh A patients (>60%) had lower rates of
downstaging success than studies with less Child-
Pugh A patients (0.42 versus 0.58; P 5 0.019); how-
ever, this difference was not statistically significant.
There was no significant difference in downstaging
success when studies were stratified into high- and
low-quality studies (55% versus 0.43; P 5 0.28).
Post-LT Recurrence
In total, 58 (0.16; 95% CI, 0.11-0.23) patients had
HCC recurrence after LT; although studies had lower
heterogeneity in terms of recurrence rates (I2 5
33.5%), there were substantial variations in the time-
to-recurrence (Table 2). Similarly, wait times before
LT were heterogeneous and inconsistently reported
(Table 2). In a sensitivity analysis excluding studies
that allowed for tumor thrombus, the pooled post-LT
recurrence rate was 0.16 (95% CI, 0.11-0.23). There
was no significant difference in recurrence rates
between retrospective and prospective studies (0.18
versus 0.15, respectively; P 5 0.86; Fig. 4). Two of the
prospective studies mandated a 3-month waiting time
before listing for LT,21,25 whereas none of the other
studies that were included had a similar requirement.
The recurrence rate after LT did not differ significantly
by downstaging modality (0.17 for TACE versus 0.26
for TARE; P 5 0.40; Fig. 5). Studies using multimodal
downstaging techniques also had a similar pooled
recurrence rate of 0.10 (95% CI, 0.03-0.18; I2, 19%; P
5 0.29). Studies with a high proportion of Child-Pugh
A patients had a similar recurrence rate versus those
with a low proportion of Child-Pugh A patients (13%
versus 0.17; P 5 0.90). Finally, recurrence rates did
not differ by study quality, with high-quality studies
having a recurrence rate of 0.20 6 0.11 and low-
quality studies having a recurrence rate of 0.15 6
0.06 (P 5 0.58).
Post-LT Survival
There was variability in reporting of survival data,
with several studies reporting 1-year and 3-year sur-
vival rates, others reporting mean or median survival,
and some simply providing a Kaplan-Meier curve.
Some studies reported survival as an intention-to-
treat analysis starting at time of downstaging,
whereas others reported survival starting at time of
LT for the subset of patients who were successfully
downstaged. Most studies with post-LT survival data
Figure 5. Pooled post-LT HCC recurrence stratified by treatment modality (TACE versus TARE).
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reported 1-year survival rates exceeding 90% (range,
87%-100%; Table 2); however, there was substantial
variability in long-term survival rates. Although some
studies had 4- or 5-year survival rates exceeding
90%,13,29 others reported lower survival rates of
approximately 70%.16,23,27 Heterogeneity in reporting
of the data prevented pooling of survival data or
meaningful subgroup analyses.
DISCUSSION
Downstaging HCC to within Milan criteria allows
patients with advanced HCC to potentially have a
curative treatment option. Overall, our pooled analy-
sis shows that nearly half of the patients will achieve
successful downstaging once initiated. However,
downstaging is associated with higher posttransplant
HCC recurrence rates compared to published data on
patients who present within Milan. There appears to
be little difference in success rates or posttransplant
outcomes by downstaging modality; however, there
are no randomized data comparing modalities.
Although the high posttransplant recurrence rates
in this study are discouraging, it is worth noting that
most studies to date have been retrospective in
nature. We found significantly higher success rates in
prospectively conducted studies compared to retro-
spective analyses. Similarly, post-LT recurrence rates
were lower, although this difference did not reach sta-
tistical significance. These differences in outcomes
were likely related to differences in study design
including (1) stricter patient selection with more
defined and limited tumor burden, (2) mandatory wait
times before LT, and (3) higher consistency in quality
of downstaging modalities. For example, the prospec-
tive study by Yao et al.25 used strict inclusion criteria
and a mandatory wait time before LT, resulting in the
highest downstaging success rate and a lower recur-
rence rate than other included studies. A priori inclu-
sion criteria for downstaging protocols appears to be a
rational approach to maximizing the probability of
success of achieving Milan criteria and reducing the
risk of posttransplant recurrence. Other potential
strategies to reduce posttransplant recurrence may
include a mandatory waiting time and/or use of bio-
marker (eg, alpha-fetoprotein or des-gamma-carboxy-
prothrombin) cutoffs before consideration of
transplantation in downstaging candidates.32 Only 2
studies included in our study, both prospective in
nature, included a mandatory waiting period before
listing for transplantation, emphasizing the impor-
tance of an institutional downstaging protocol.21,25
Although we found no difference in outcomes
according to downstaging modality (TACE versus
TARE), published data on TARE-related downstaging
success and post-LT recurrence are limited. At least 1
of the TARE studies investigated downstaging exclu-
sively in patients with tumor thrombus, which likely
underestimates the potential effectiveness of TARE for
downstaging in patients with liver-limited disease.18
Similarly, data on other emerging modalities, such as
SBRT, are also sparse. Although a multimodal treat-
ment approach yielded the best outcome in our analy-
sis, all multimodal studies had a proportion (8%) of
patients who underwent surgical resection for down-
staging. Patients eligible for surgery are typically with-
out significant portal hypertension and therefore may
have different clinical outcomes than other patients
who receive locoregional therapies. Further studies
evaluating and comparing different downstaging
modalities are clearly needed.
One of the most notable findings of our systematic
review is the substantial heterogeneity and limitations
of data evaluating downstaging. First, there was sub-
stantial variation in baseline tumor burden—with
some studies only including patients within University
of California–San Francisco (UCSF) criteria (Barcelona
Clinic Liver Cancer [BCLC] stage B), whereas others
included patients with tumor thrombus (BCLC stage
C). Second, there was variation in response assess-
ment, with some studies using entire lesion size
(RECIST or WHO) and others using viable tumor size
(EASL or mRECIST). Third, a small number of studies
included a mandatory waiting period, although most
did not. Finally, we found important factors such as
liver function, tumor burden at entry, and wait time
before LT were not consistently reported.33
To improve the quality of literature evaluating HCC
downstaging, we propose minimum reporting criteria
for future studies (Table 3). Standardizing reporting of
downstaging would allow for better understanding of
TABLE 3. Proposed Minimum Reporting Criteria for
Downstaging Studies
Patient characteristics
Demographics
Etiology of liver disease
Liver function (Child-Pugh class, presence of
decompensation)
Center characteristics
LT volume
Median wait time for LT
Downstaging inclusion protocol
Tumor characteristics
Tumor burden (dominant tumor size, cumulative
tumor size)
BCLC tumor stage
Imaging modality and criteria used to measure
tumor size (mRECIST, WHO, EASL)
Treatment details
Treatment modalities used (type, number)
Interval between initial downstaging and listing for
LT
Treatments received while awaiting LT
Wait time on the LT list
Time from initiation of downstaging to LT
LT details
Total length of follow-up post-LT
Immunosuppression protocol post-LT
Overall and recurrence-free graft survival
Overall and recurrence-free patient survival
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data moving forward. Ideally, a multicenter well-
powered trial of downstaging protocols would be con-
ducted to understand the optimal tumor burden,
downstaging modality and protocol, and wait time
before LT in order to achieve the best outcomes for
downstaged patients. Alternatively, more stringent
reporting of post-LT HCC recurrence rates could be
mandated by the United Network for Organ Sharing
in order to better characterize recurrence risk in this
population of patients.
Our study has many strengths and limitations. As
noted above, the included studies are heterogeneous
with variable patient populations with regards to
tumor burden, liver function, therapy received, and
posttreatment response criteria. These differences
make studies difficult to directly compare and thereby
limit our ability to make strong conclusions about the
superiority of one modality or protocol over another.
Second, we did not have patient-level data to perform
additional analyses on the basis of tumor burden or
liver function. Given the small cohorts of single-center
patient data, included studies may suffer from report-
ing bias. Our funnel plots showed no evidence of bias;
however, this may reflect the large number of small
studies included in this meta-analysis.34 In addition,
non-English studies were excluded because of practi-
cal considerations, which may further bias the
results. Nevertheless, our meta-analysis provides an
important comprehensive summary of the
downstaging success and posttransplant outcomes as
reported in the literature. Furthermore, we highlight
notable limitations of the current literature, which
have informed our recommendations for minimum
reporting criteria moving forward to improve our evi-
dence base for downstaging.
In summary, we have shown that downstaging
patients outside of Milan can be achieved in approxi-
mately half of all patients; however, post-LT recur-
rence is higher than what has been reported in
patients who present within Milan. It is important to
note that in well-designed studies with downstaging
protocols, equivalent posttransplant results between
downstaged patients and those who present within
Milan criteria can be achieved.25 Although compari-
sons of downstaging modalities and protocols are dif-
ficult given the heterogeneity and limitations of
current data, a protocolized approach with carefully
patient selection and a standardized downstaging pro-
tocol is likely necessary to yield optimal outcomes.
Large prospective studies, using standardized report-
ing criteria, are needed to compare downstaging
modalities and protocols to optimize success and
posttransplant survival in this cohort of patients.
REFERENCES
1. El-Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-
Woody M, McBride R, McGlynn KA. Treatment and out-
comes of treating of hepatocellular carcinoma among
Medicare recipients in the United States: a population-
based study. J Hepatol 2006;44:158-166.
2. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB,
Rayhill SC, Pelletier SJ. Liver transplantation in the
United States, 1999–2008. Am J Transplant 2010;10(pt 2):
1003-1019.
3. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A,
Bozzetti F, et al. Liver transplantation for the treatment
of small hepatocellular carcinomas in patients with cir-
rhosis. N Engl J Med 1996;334:693-699.
4. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL,
Roberts JP. Liver transplantation for hepatocellular carci-
noma: comparison of the proposed UCSF criteria with
the Milan criteria and the Pittsburgh modified TNM crite-
ria. Liver Transpl 2002;8:765-774.
5. Leung JY, Zhu AX, Gordon FD, Pratt DS, Mithoefer A,
Garrigan K, et al. Liver transplantation outcomes for
early-stage hepatocellular carcinoma: results of a multi-
center study. Liver Transpl 2004;10:1343-1354.
6. Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA.
Changing hepatocellular carcinoma incidence and liver
cancer mortality rates in the United States. Am J Gastro-
enterol 2014;109:542-553.
7. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche
PC, Ioannidis JP, et al. The PRISMA statement for report-
ing systematic reviews and meta-analyses of studies that
evaluate health care interventions: explanation and elab-
oration. PLoS Med 2009;6:e1000100.
8. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson
GD, Rennie D, et al. Meta-analysis of observational stud-
ies in epidemiology: a proposal for reporting. Meta-analy-
sis Of Observational Studies in Epidemiology (MOOSE)
group. JAMA 2000;283:2008-2012.
9. Wells GA, Shea B, O’Connell D, Peterson J. The
Newcastle-Ottawa Scale (NOS) for assessing the quality of
nonrandomised studies in meta-analyses. 3rd Sympo-
sium on Systematic Reviews: Beyond the Basics; 2000.
10. Stuart A. Kendall’s Advanced Theory of Statistics. 6th ed.
Hoboken, NJ: Wiley; 2010.
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Meas-
uring inconsistency in meta-analyses. BMJ 2003;327:
557-560.
12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in
meta-analysis detected by a simple, graphical test. BMJ
1997;315:629-634.
13. Chapman WC, Majella Doyle MB, Stuart JE,
Vachharajani N, Crippin JS, Anderson CD, et al. Out-
comes of neoadjuvant transarterial chemoembolization to
downstage hepatocellular carcinoma before liver trans-
plantation. Ann Surg 2008;248:617-625.
14. De Luna W, Sze DY, Ahmed A, Ha BY, Ayoub W, Keeffe
EB, et al. Transarterial chemoinfusion for hepatocellular
carcinoma as downstaging therapy and a bridge toward
liver transplantation. Am J Transplant 2009;9:1158-1168.
15. Green TJ, Rochon PJ, Chang S, Ray CE Jr, Winston H,
Ruef R, et al. Downstaging disease in patients with hepa-
tocellular carcinoma outside of Milan criteria: strategies
using drug-eluting bead chemoembolization. J Vasc
Interv Radiol 2013;24:1613-1622.
16. Otto G, Herber S, Heise M, Lohse AW, M€onch C,
Bittinger F, et al. Response to transarterial chemoemboli-
zation as a biological selection criterion for liver trans-
plantation in hepatocellular carcinoma. Liver Transpl
2006;12:1260-1267.
17. I~narrairaegui M, Pardo F, Bilbao JI, Rotellar F, Benito A,
D’Avola D, et al. Response to radioembolization with
yttrium-90 resin microspheres may allow surgical treat-
ment with curative intent and prolonged survival in pre-
viously unresectable hepatocellular carcinoma. Eur J
Surg Oncol 2012;38:594-601.
18. Pracht M, Edeline J, Lenoir L, Latournerie M, Mesbah H,
Audrain O, et al. Lobar hepatocellular carcinoma with
LIVER TRANSPLANTATION, Vol. 21, No. 9, 2015 PARIKH ET AL. 1151
ipsilateral portal vein tumor thrombosis treated with
yttrium-90 glass microsphere radioembolization: prelimi-
nary results. Int J Hepatol 2013;2013:827649.
19. Tohme S, Sukato D, Chen HW, Amesur N, Zajko AB,
Humar A, et al. Yttrium-90 radioembolization as a bridge
to liver transplantation: a single-institution experience.
J Vasc Interv Radiol 2013;24:1632-1638.
20. Barakat O, Wood RP, Ozaki CF, Ankoma-Sey V, Galati J,
Skolkin M, et al. Morphological features of advanced
hepatocellular carcinoma as a predictor of downstaging
and liver transplantation: an intention-to-treat analysis.
Liver Transpl 2010;16:289-299.
21. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M,
Ercolani G, et al. Liver transplantation for hepatocellular
carcinoma: results of downstaging in patients initially
outside the Milan selection criteria. Am J Transplant
2008;8:2547-2557.
22. BovaV,MiragliaR,MaruzzelliL,VizziniGB,LucaA.Predictive
factors of downstaging of hepatocellular carcinoma beyond
theMilancriteriatreatedwithintra-arterialtherapies.Cardi-
ovascInterventRadiol2013;36:433-439.
23. Jang JW, You CR, Kim CW, Bae SH, Yoon SK, Yoo YK,
et al. Benefit of downsizing hepatocellular carcinoma in a
liver transplant population. Aliment Pharmacol Ther
2010;31:415-423.
24. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S,
Mulcahy MF, Ryu RK, et al. A comparative analysis of
transarterial downstaging for hepatocellular carcinoma:
chemoembolization versus radioembolization. Am J
Transplant 2009;9:1920-1928.
25. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix
O, et al. Downstaging of hepatocellular cancer before
liver transplant: Long-term outcome compared to tumors
within Milan criteria. Hepatology 2015;61:1968-1977.
26. Graziadei IW, Sandmueller H, Waldenberger P,
Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoem-
bolization followed by liver transplantation for hepatocellu-
lar carcinoma impedes tumor progression while on the
waiting list and leads to excellent outcome. Liver Transpl
2003;9:557-563.
27. Shi XJ, Jin X, Wang MQ, Wei LX, Ye HY, Liang YR, et al.
Outcomes of loco-regional therapy for downstaging of
hepatocellular carcinoma prior to liver transplantation.
Hepatobiliary Pancreat Dis Int 2011;10:143-150.
28. Concejero A, Chen CL, Wang CC, Wang SH, Lin CC, Liu
YW, et al. Living donor liver transplantation for hepato-
cellular carcinoma: a single-center experience in Taiwan.
Transplantation 2008;85:398-406.
29. El-Gazzaz G, Aucejo FN, Menon KN, Miller CM, Quintini C,
Eghtesad B, et al. Outcome of pre-Transplant Locoregional
Therapy to Downstage Hepatocellular Carcinoma (HCC).
Abstracts of the American Association for the Study of Liver
Diseases 61st Annual Meeting and Postgraduate Course.
October 29-November 2, 2010; Boston, Massachusetts,
USA. Hepatology 2010;52(suppl):320A-1291A.
30. Conteh L, Geevarghese S. Downstaging hepatocellular
carcinoma: equivalent post-transplant outcomes
among patients initially categorized beyond and within
Milan Criteria. International Liver Cancer Association
Annual Meeting, September 2013; Washington,
DC:ILCA; 2013.
31. Toso C, Mentha G, Kneteman NM, Majno P. The place of
downstaging for hepatocellular carcinoma. J Hepatol
2010;52:930-936.
32. Schlansky B, Chen Y, Scott DL, Austin D, Naugler WE.
Waiting time predicts survival after liver transplantation
for hepatocellular carcinoma: a cohort study using the
United Network for Organ Sharing registry. Liver Transpl
2014;20:1045-1056.
33. Hunter JP, Saratzis A, Sutton AJ, Boucher RH, Sayers
RD, Bown MJ. In meta-analyses of proportion studies,
funnel plots were found to be an inaccurate method of
assessing publication bias. J Clin Epidemiol 2014;67:
897-903.
1152 PARIKH ET AL. LIVER TRANSPLANTATION, September 2015
